Prostate specific antigen for early detection of prostate cancer: longitudinal study
BMJPublished 24 September 2009Open access
B Holmström, Mattias Johansson, Anders Bergh, Ulf‐Håkan Stenman, Göran Hallmans, P. Stattin
Citations132
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
No single cut-off value for prostate specific antigen concentration attained likelihood ratios formally required for a screening test, and Prostate specific antigen concentrations below 1.0 ng/ml virtually ruled out a prostate cancer diagnosis during the follow-up.
Abstract
No single cut-off value for prostate specific antigen concentration attained likelihood ratios formally required for a screening test. Prostate specific antigen concentrations below 1.0 ng/ml virtually ruled out a prostate cancer diagnosis during the follow-up. Additional biomarkers for early detection of prostate cancer are needed before population based screening for prostate cancer should be introduced.
Keywords
Medicine
New England Journal of MedicineScreening and Prostate-Cancer Mortality in a Randomized European Study
3,959 Citations2009Fritz H. Schröder, Jonas Hugosson +21 more
PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
JAMAUsers' guides to the medical literature
2,981 Citations1993Gordon Guyatt
A 55-year-old man who had his serum cholesterol level measured at a shopping mall 2 months ago has an elevated cholesterol level, but before deciding on a treatment recommendation, you elect to find out just how big a reduction in the risk of CHD this patient could expect from a cholesterollowering diet or drug therapy.
New England Journal of MedicineMortality Results from a Randomized Prostate-Cancer Screening Trial
2,917 Citations2009Gerald L. Andriole, E. David Crawford +22 more
After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.
BMJDiagnostic tests 4: likelihood ratios
1,579 Citations2004Jonathan J Deeks, Douglas G. Altman
Likelihood ratios are alternative statistics for summarising diagnostic accuracy, which have several particularly powerful properties that make them more useful clinically than other statistics.
American Journal of EpidemiologyLimitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker
1,258 Citations2004M. S. Pepe
An illustration of the relation between odds ratios and receiver operating characteristic curves shows, for example, that a marker with an odds ratio of as high as 3 is in fact a very poor classification tool.
JAMAA Prospective Evaluation of Plasma Prostate-Specific Antigen for Detection of Prostatic Cancer
734 Citations1995Peter H. Gann
A single PSA measurement had a relatively high sensitivity and specificity for detection of prostate cancers that arose within 4 years and cost and the ability of current treatments to improve the prognosis of screen-detected cases are considered.
JAMAOperating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower
697 Citations2005Ian M. Thompson
There is no cutpoint of PSA with simultaneous high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather a continuum of prostate cancer risk at all values of P SA.
New England Journal of MedicineThe Limitations of Risk Factors as Prognostic Tools
468 Citations2006James H. Ware
Research has shown that a risk factor must have a much stronger association with the disease outcome than the authors ordinarily see in etiologic research if it is to provide a basis for early diagnosis or prediction in individual patients.
New England Journal of MedicineProstate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer
433 Citations2001Marc Barry
Evidence supporting various strategies is presented, followed by a review of formal guidelines, when they exist, and the article ends with the author's clinical recommendations.
International Journal of CancerLarge‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial
287 Citations2001Harry J. de Koning, Anssi Auvinen +12 more
Two large‐scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial in the USA and the European Randomized Screening for Prostate Cancer (ERSPC) trial in Europe are currently under way, aimed at assessing whether screening reduces prostate cancer mortality.
The LancetSerum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer
271 Citations1994U-H Stenman, J. Leinonen +4 more
The results suggest it is advisable to confine screening for prostate cancer to men with a life expectancy of clearly more than 10 years--ie, younger men, who have the greatest chance to benefit from early detection.
CA A Cancer Journal for CliniciansCancer Screening in the United States, 2008: A Review of Current American Cancer Society Guidelines and Cancer Screening Issues
215 Citations2008RA Smith, Vilma Cokkinides +1 more
The current ACS guidelines are summarized, an update of the most recent data pertaining to participation rates in cancer screening from the Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System and the National Health Interview Survey are provided, and some issues related to access to care are addressed.
Journal of Clinical OncologyLong-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years
204 Citations2007Hans Lilja, David Ulmert +7 more
A single PSA test at age 44 to 50 years predicts subsequent clinically diagnosed prostate cancer, which raises the possibility of risk stratification for prostate cancer screening programs.
Scandinavian Journal of Primary Health CareReduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care
189 Citations1998Lars Weinehall
The primary health care system in Sweden might serve as a useful base for educational health counselling, at least within a community intervention programme, for all levels of society.
JAMAComparative Efficiency of Prostate-Specific Antigen Screening Strategies for Prostate Cancer Detection
162 Citations2000Kevin S. Ross
Recognizing that the efficacy of PSA screening is unproved, the standard strategy of annual PSA screenings beginning at age 50 years appears to be less effective and more resource intensive compared with a strategy that begins earlier but screens biennially instead of annually.
Journal of Clinical OncologyHigh Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened Cohort
154 Citations2004Pär Stattin, Sabina Rinaldi +4 more
CancerResults of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma
132 Citations2004Jonas Hugosson, Gunnar Aus +3 more
The purpose of the current study was to evaluate the effectiveness of a prostate carcinoma screening program in which serum prostate‐specific antigen (PSA) levels were measured.
Scandinavian Journal of Urology and NephrologyClinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005
118 Citations2007Jan Adolfsson, Hans Garmo +17 more
All changes in the register seen over time are consistent with increased diagnostic activity, especially PSA testing, resulting in an increased number of cases with early disease, predominantly tumors in category T1c.
PubMedEvaluation of the Abbott IMx automated immunoassay of prostate-specific antigen.
105 Citations1992R L Vessella, Jennifer Noteboom +1 more
Scandinavian Journal of Urology and NephrologyPrognostic value of serum markers for prostate cancer
92 Citations2005Ulf‐Håkan Stenman, Per‐Anders Abrahamsson +6 more
Markers of neuroendocrine differentiation are useful for the monitoring of androgen-independent disease and various bone markers are useful in patients with metastatic disease, and assays for minor subfractions of PSA and other new markers may provide additional prognostic information.
Archives of Internal MedicineIndividualized Screening Interval for Prostate Cancer Based on Prostate-Specific Antigen Level
89 Citations2005Gunnar Aus, Jan‐Erik Damber +4 more
Retesting intervals should be individualized on the basis of the PSA level, and the large group of men with PSA levels of less than 1 ng/mL can safely be scheduled for a 3-year testing interval.
BMJProspective observational study to assess value of prostate specific antigen as screening test for prostate cancer
76 Citations1995Carol Parkes, N J Wald +7 more
Measurement of this antigen is a good enough screening test to justify a randomised controlled trial to determine any reduction in mortality from prostate cancer.
The Journal of UrologyStrategies Combining Total and Percent Free Prostate Specific Antigen for Detecting Prostate Cancer: A Prospective Evaluation
71 Citations2002Peter H. Gann, Jing Ma +2 more
These results demonstrate that in a prospective setting with long-term followup free PSA strategies can be identified that decrease unnecessary biopsies, while preserving or even improving cancer detection, without the need to weigh subjectively the trade-offs and relative costs of false-negative and false-positive results.
The Journal of UrologyVALIDITY OF THE PROSTATE SPECIFIC ANTIGEN TEST FOR PROSTATE CANCER SCREENING: FOLLOWUP STUDY WITH A BANK OF 21,000 SERA IN FINLAND
57 Citations2001Matti Hakama, Ulf‐Håkan Stenman +4 more
PSA is a valid screening test for prostate cancer, which compares favorably with mammography for breast cancer, however, until an effect on mortality has been shown, routine screening cannot be recommended.
American Journal of TherapeuticsEvidence-based Medical Perspectives: The Evolving Role of PSA for Early Detection, Monitoring of Treatment Response, and as a Surrogate End Point of Efficacy for Interventions in Men with Different Clinical Risk States for the Prevention and Progression of Prostate Cancer
51 Citations2004Ronald Lieberman
This commentary reviews and critically evaluates the emerging body of new data and concludes that some metric of PSA as a biomarker alone or as part of a panel of other serum proteomic markers or tissue-derived multiplex gene expression arrays will be around for years to come as a useful tool for risk stratification, early detection, prognosis, prediction, and as an SE of efficacy for prevention and treatment of PC.
British Journal of CancerSpecificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
32 Citations2007Liisa Määttänen, Matti Hakama +7 more
The specificity of PSA screening in the Finnish screening trial is acceptable, and further improvement in specificity could, however, improve acceptability of screening and decrease screening costs.
The Journal of UrologyPROSTATE CANCER SCREENING WITHIN A PROSTATE SPECIFIC ANTIGEN RANGE OF 3 TO 3.9 NG./ML.: A COMPARISON OF DIGITAL RECTAL EXAMINATION AND FREE PROSTATE SPECIFIC ANTIGEN AS SUPPLEMENTAL SCREENING TESTS
29 Citations2001Tuukka Mäkinen, Teuvo L.J. Tammela +7 more
Using percent free PSA increased the detection rate of aggressive disease compared with digital rectal examination and provided higher specificity than PSA alone.
The Journal of UrologyINTERVAL AFTER PROSTATE SPECIFIC ANTIGEN TESTING AND SUBSEQUENT RISK OF INCURABLE PROSTATE CANCER
18 Citations2001Siu‐Long Yao, Grace L. Lu‐Yao
Patients who choose to undergo PSA testing may be tested on a biennial instead of annual basis without an increased risks of nonlocalized cancer and decreasing the frequency may lead to fewer prostate biopsies.
The Journal of UrologyResults of a Randomized, Population-Based Study of Biennial Screening Using Serum Prostate-Specific Antigen Measurement to Detect Prostate Carcinoma
5 Citations2004Patrick C. Walsh
Biennial PSA screening was very successful in diagnosing prostate carcinoma at an early stage, when curative treatment typically is effective, and decreased mortality should be observed on long-term follow-up.
Therapeutische UmschauGezielter Einsatz des Tumormarkers PSA
4 Citations2008Maciej Kwiatkowski, P Stieber +2 more
PSA and especially PSA doubling time is a promising marker to identify men at risk for whom salvage-radiotherapy, salvage prostatectomy or hormonal therapy can be an option, however the benefit in survival must be weight against a possible loss in quality of life.